{"id":"neuvax-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"NeuVax uses a peptide-based immunotherapy approach designed to activate T-cell responses against HER2-positive tumors. The vaccine contains a HER2-derived peptide (E75) combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) to enhance immune activation. This approach aims to prevent recurrence in patients with HER2-positive breast cancer by training the immune system to target residual cancer cells.","oneSentence":"NeuVax is a therapeutic cancer vaccine that stimulates the immune system to recognize and attack cancer cells expressing the HER2 protein.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:22:59.178Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HER2-positive breast cancer (adjuvant setting, Phase 3)"}]},"trialDetails":[{"nctId":"NCT02297698","phase":"PHASE2","title":"Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients","status":"COMPLETED","sponsor":"Cancer Insight, LLC","startDate":"2014-10","conditions":"Breast Cancer","enrollment":100},{"nctId":"NCT01479244","phase":"PHASE3","title":"Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence","status":"COMPLETED","sponsor":"Galena Biopharma, Inc.","startDate":"2011-11","conditions":"Breast Cancer With Low to Intermediate HER2 Expression","enrollment":758}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["E75 peptide acetate , WFI, sargramostim, GM-CSF","E75 peptide (KIFGSLAFL, HER2/neu, 369-377)","GM-CSF (sargramostim)","nelipepimut-S"],"phase":"phase_3","status":"active","brandName":"NeuVax™ vaccine","genericName":"NeuVax™ vaccine","companyName":"Galena Biopharma, Inc.","companyId":"galena-biopharma-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"NeuVax is a therapeutic cancer vaccine that stimulates the immune system to recognize and attack cancer cells expressing the HER2 protein. Used for HER2-positive breast cancer (adjuvant setting, Phase 3).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}